X0306 4 2017-11-21 0 0001604950 scPharmaceuticals Inc. SCPH 0001589314 5AM Partners IV, LLC C/O SCPHARMACEUTICALS INC 2400 DISTRICT AVENUE SUITE 310 BURLINGTON MA 01830 0 0 1 0 0001589315 5AM Ventures IV, L.P. 501 2ND STREET, SUITE 350 SAN FRANCISCO CA 94107 0 0 1 0 0001593361 5AM Co-Investors IV, L.P. 501 2ND STREET, SUITE 350 SAN FRANCISCO CA 94107 0 0 1 0 0001598549 Schwab Andrew J. 501 2ND STREET, SUITE 350 SAN FRANCISCO CA 94107 0 0 1 0 0001240357 DIEKMAN JOHN D 501 2ND STREET, SUITE 350 SAN FRANCISCO CA 94107 0 0 1 0 0001219014 ROCKLAGE SCOTT M 501 2ND STREET, SUITE 350 SAN FRANCISCO CA 94107 0 0 1 0 Common Stock 2017-11-21 4 C 0 1483107 A 1483107 I by 5AM Ventures IV, L.P. Common Stock 2017-11-21 4 C 0 1011623 A 2494730 I by 5AM Ventures IV, L.P. Common Stock 2017-11-21 4 P 0 628572 14.00 A 3123302 I by 5AM Ventures IV, L.P. Common Stock 2017-11-21 4 C 0 61795 A 61795 I by 5AM Co-Investors IV, L.P. Common Stock 2017-11-21 4 C 0 42150 A 103945 I by 5AM Co-Investors IV, L.P. Common Stock 2017-11-21 4 P 0 26190 14.00 A 130135 I by 5AM Co-Investors IV, L.P. Series A Preferred Stock 2017-11-21 4 C 0 10649003 0.00 D Common Stock 1483107 0 I by 5AM Ventures IV, L.P. Series B Preferred Stock 2017-11-21 4 C 0 7263649 0.00 D Common Stock 1011623 0 I by 5AM Ventures IV, L.P. Series A Preferred Stock 2017-11-21 4 C 0 443708 0.00 D Common Stock 61795 0 I by 5AM Co-Investors IV, L.P. Series B Preferred Stock 2017-11-21 4 C 0 302652 0.00 D Common Stock 42150 0 I by 5AM Co-Investors IV, L.P. Represents the total number of shares of Common Stock received by 5AM Ventures IV, L.P., upon conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. 5AM Partners IV, LLC is the general partner of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (the "5AM Funds"). Dr. John D. Diekman, Andrew J. Schwab, and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC. 5AM Partners IV, LLC may be deemed to have sole voting and investment power over the shares beneficially owned by the 5AM Funds. Dr. Diekman, Mr. Schwab, and Dr. Rocklage may be deemed to have shared voting and investment power over the shares beneficially by the 5AM Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Represents the total number of shares of Common Stock received by 5AM Ventures IV, L.P., upon conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. Represents the total number of shares of Common Stock received by 5AM Co-Investors IV, L.P., upon conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. Represents the total number of shares of Common Stock received by 5AM Co-Investors IV, L.P., upon conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. /s/ Courtney Gaughan, Attorney-in-Fact for 5AM Partners IV, LLC 2017-11-21 /s/ Courtney Gaughan, Attorney-in-Fact for 5AM Ventures IV, L.P. 2017-11-21 /s/ Courtney Gaughan, Attorney-in-Fact for 5AM Co-Investors IV, L.P. 2017-11-21 /s/ Andrew J. Schwab 2017-11-21 /s/ John D. Diekman 2017-11-21 /s/ Scott M. Rocklage 2017-11-21